2007
DOI: 10.1016/j.ijpharm.2007.03.014
|View full text |Cite
|
Sign up to set email alerts
|

Cationic supported lipid bilayers for antigen presentation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
77
0
3

Year Published

2010
2010
2023
2023

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 42 publications
(83 citation statements)
references
References 19 publications
3
77
0
3
Order By: Relevance
“…This aggregation did not occur in the presence of DDA-BF when using small OMV protein concentrations (288 ± 7 nm for 25 μg/mL of protein in 0.1 mM DDA). This result is similar to that observed by Lincopan et al (2007). 48 Animals were immunized with 200 μL of antigen injected into 2 sites (100 μL/site) subcutaneously, which totaled 5 μg of protein/animal.…”
Section: Methodssupporting
confidence: 86%
See 1 more Smart Citation
“…This aggregation did not occur in the presence of DDA-BF when using small OMV protein concentrations (288 ± 7 nm for 25 μg/mL of protein in 0.1 mM DDA). This result is similar to that observed by Lincopan et al (2007). 48 Animals were immunized with 200 μL of antigen injected into 2 sites (100 μL/site) subcutaneously, which totaled 5 μg of protein/animal.…”
Section: Methodssupporting
confidence: 86%
“…This result is similar to that observed by Lincopan et al (2007). 48 Animals were immunized with 200 μL of antigen injected into 2 sites (100 μL/site) subcutaneously, which totaled 5 μg of protein/animal. The animals were immunized according to the scheme showed in Table 2.…”
Section: Methodssupporting
confidence: 86%
“…When Quil A is combined with cholesterol (QAC) it forms helical, nanometer scale worm-like micelles (Mitra and Dungan 2001). DDA is a cationic, micelle-forming surfactant (Lincopan et al 2007). In this study, three experimental vaccines, adjuvanted with Q-series adjuvants were compared to commercially available vaccines.…”
Section: Introductionmentioning
confidence: 99%
“…In our group, we have been using the BF for novel applications such as adsorption of hydrophobic drugs 19,32,33 and presentation of antigens to the immune system. 23,27 Previous studies on the interaction between such BF and oppositely charged PSS microspheres revealed that, over a range of low salt concentrations (0.5-5 mM NaCl), there was fusion of adjacent BF around the microsphere with production of a continuous bilayer coating. 20 However, it was also previously described that the DODAB bilayer exhibited hydrophobic defects (exposure of hydrophobic regions of the bilayer to the water phase) in the presence of NaCl 20 so that the hydrophobic effect could indeed drive HRP to integration with the bilayer core.…”
Section: Discussionmentioning
confidence: 99%
“…In this sequence, 0.75 mL of the stock PSS dispersion, 0.03 mL of a 1 mM DODAB BF dispersion and 2.220 mL of a 1 mM NaCl solution were mixed and allowed to interact for 1 h at 25 C yielding final concentrations of 5 Â 10 9 PSS particles/mL and 0.01 mM DODAB, since this last concentration is the one required to cover each particle with a DODAB bilayer. 18,27 In experiments aiming at evaluation of particle concentration effects, the previously quoted proportion between particles and DODAB was maintained, e.g., at 0.5 Â 10 9 PSS particles/mL, 0.03 mL of a 0.1 mM DODAB dispersion was added to produce the cationic biomimetic particles. Particles concentration ranged from 0.5 to 16.6 Â 10 9 particles/mL (see Table 1).…”
Section: Preparation Of Pss/dodab Biomimetic Particlesmentioning
confidence: 99%